$2.002.00 +0.070.07 |(+3.633.63 %)
52W H: 2.6152W L: 1.33Beta: 0.92
About Inhibikase Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.inhibikase.com/
Frequently Asked Questions
What is the 52-week range for IKT?
The 52-week high is $2.61 and the 52-week low is $1.33.
What is the P/E ratio for IKT?
The P/E ratio data is currently unavailable.
What is the dividend yield for IKT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -46.90%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -5981.25%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.44.
Analyst Recommendation Trends
Wall Street analyst consensus for IKT over the last few months:
2026-09-01
Buy: 7
S.Buy: 5
Hold: 1
Sell: 0
2026-08-01
Buy: 7
S.Buy: 5
Hold: 1
Sell: 0
2026-07-01
Buy: 7
S.Buy: 4
Hold: 1
Sell: 0
2026-06-01
Buy: 7
S.Buy: 3
Hold: 1
Sell: 0
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-30 | BERMAN DENNIS N | -21,854 | - | - |
| 2026-07-30 | BERMAN DENNIS N | +21,854 | $1.26 | $27,536 |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | +18,030,000 | - | - |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | -18,030,000 | - | - |
| 2026-02-21 | Cabell Christopher | -338,282 | - | - |
| 2026-02-21 | Aurentz Vincent | -255,299 | - | - |
| 2026-02-21 | Munshi Amit | -19,089 | - | - |
| 2026-01-05 | Cabell Christopher | +900,117 | - | - |
| 2026-01-05 | Iwicki Mark T | +4,982,706 | - | - |
| 2026-01-05 | McIntyre David | +986,319 | - | - |
| 2025-11-21 | Sands Capital Alternatives, LLC | +2,068,965 | $1.45 | $2,999,999 |